Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
    Hashguchi, Mizuha Haraguchi
    Sato, Takashi
    Watanabe, Rinako
    Kagyo, Junko
    Matsuzaki, Tomohiko
    Domoto, Hideharu
    Kato, Terufumi
    Nakahara, Yoshiro
    Yokose, Tomoyuki
    Hiroshima, Yukihiko
    Shiomi, Tetsuya
    THORACIC CANCER, 2021, 12 (18) : 2504 - 2507
  • [42] NCOA1-ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
    Cao, Qi
    Liu, Zhiguang
    Huang, Yanhua
    Qi, Chuang
    Yin, Xiaowei
    ONCOTARGETS AND THERAPY, 2019, 12 : 1071 - 1074
  • [43] Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report
    Leyrat, Brice
    Durando, Xavier
    Veyssiere, Hugo
    Bernadach, Maureen
    ONCOTARGETS AND THERAPY, 2021, 14 : 3949 - 3958
  • [44] ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib
    Li, X.
    Xu, C.
    Xu, S.
    Wang, W.
    Ye, J.
    Zhu, Y.
    Ge, T.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1049 - S1049
  • [45] THE CASE REPORT OF LUNG ADENOCARCINOMA THYROID METASTASIS OF ALK REARRANGEMENT
    Tian, Tian
    Hong, Fu
    Zhang, Zhihong
    Qian, Liting
    ACTA MEDICA MEDITERRANEA, 2020, 36 (03): : 1307 - 1310
  • [46] Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
    Zhang, Xiangming
    Ni, Kai
    Chen, Huijun
    ONCOTARGETS AND THERAPY, 2023, 16 : 87 - 90
  • [47] Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
    Yan, Ning
    Huang, Si
    Li, Lin
    Guo, Qian
    Geng, Di
    Zhang, Hui
    Guo, San
    Li, Xing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [48] CLINICAL AND PROGNOSTIC IMPLICATION OF ALK AND ROS1 REARRANGEMENT IN NEVER SMOKER WITH SURGICALLY RESECTED LUNG ADENOCARCINOMA
    Kim, Hye Ryun
    Kim, Min Hwan
    Lim, Sun-Min
    Kim, Eun Young
    Park, Ji Soo
    Kim, Joo Hang
    Shim, Hyo Sup
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1220 - S1220
  • [49] Rare dual MYH9-ROS1 fusion variants in a patient with lung adenocarcinoma A case report
    Luo, Tian
    Ji, Wentao
    Guo, Weihong
    Zhang, Dandan
    Liang, Jianping
    Lv, Yanhua
    MEDICINE, 2025, 104 (04) : e41350
  • [50] ROS1 fusion lung adenosquamous carcinoma patient with short-term clinical benefit after crizotinib treatment: a case report
    Cheng, Yurong
    Yang, Jiandong
    Wang, Daochao
    Yan, Dong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (03)
12345